JP2004525108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525108A5 JP2004525108A5 JP2002559447A JP2002559447A JP2004525108A5 JP 2004525108 A5 JP2004525108 A5 JP 2004525108A5 JP 2002559447 A JP2002559447 A JP 2002559447A JP 2002559447 A JP2002559447 A JP 2002559447A JP 2004525108 A5 JP2004525108 A5 JP 2004525108A5
- Authority
- JP
- Japan
- Prior art keywords
- lipopeptide
- daptomycin
- crystalline
- crystal
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010028921 Lipopeptides Proteins 0.000 claims 65
- 238000000034 method Methods 0.000 claims 59
- 108010013198 Daptomycin Proteins 0.000 claims 45
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 45
- 229960005484 daptomycin Drugs 0.000 claims 45
- 150000003839 salts Chemical class 0.000 claims 30
- 238000002425 crystallisation Methods 0.000 claims 15
- 230000008025 crystallization Effects 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000001556 precipitation Methods 0.000 claims 11
- 239000000243 solution Substances 0.000 claims 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 230000001376 precipitating effect Effects 0.000 claims 6
- -1 absorption aids Substances 0.000 claims 5
- 239000011549 crystallization solution Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 239000006174 pH buffer Substances 0.000 claims 4
- 235000013772 propylene glycol Nutrition 0.000 claims 4
- 108700022307 A54145 Proteins 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 238000011084 recovery Methods 0.000 claims 3
- 150000005846 sugar alcohols Polymers 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 2
- 239000008000 CHES buffer Substances 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 239000007995 HEPES buffer Substances 0.000 claims 2
- 239000007987 MES buffer Substances 0.000 claims 2
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 2
- 239000001639 calcium acetate Substances 0.000 claims 2
- 229960005147 calcium acetate Drugs 0.000 claims 2
- 235000011092 calcium acetate Nutrition 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000002453 shampoo Substances 0.000 claims 2
- 239000000344 soap Substances 0.000 claims 2
- 229940044613 1-propanol Drugs 0.000 claims 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 241000234314 Zingiber Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000001166 anti-perspirative effect Effects 0.000 claims 1
- 239000003213 antiperspirant Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000001354 calcium citrate Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012459 cleaning agent Substances 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 238000012835 hanging drop method Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940096405 magnesium cation Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 235000013337 tricalcium citrate Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 229940006486 zinc cation Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25626800P | 2000-12-18 | 2000-12-18 | |
| US27474101P | 2001-03-09 | 2001-03-09 | |
| US34052501P | 2001-12-13 | 2001-12-13 | |
| US34131501P | 2001-12-13 | 2001-12-13 | |
| PCT/US2001/048886 WO2002059145A1 (en) | 2000-12-18 | 2001-12-17 | Methods for preparing purified lipopeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008051874A Division JP4927003B2 (ja) | 2000-12-18 | 2008-03-03 | 精製リポペプチドの調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525108A JP2004525108A (ja) | 2004-08-19 |
| JP2004525108A5 true JP2004525108A5 (enExample) | 2005-12-22 |
Family
ID=27500563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559447A Pending JP2004525108A (ja) | 2000-12-18 | 2001-12-17 | 精製リポペプチドの調製方法 |
| JP2008051874A Expired - Lifetime JP4927003B2 (ja) | 2000-12-18 | 2008-03-03 | 精製リポペプチドの調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008051874A Expired - Lifetime JP4927003B2 (ja) | 2000-12-18 | 2008-03-03 | 精製リポペプチドの調製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20030045678A1 (enExample) |
| EP (3) | EP1343811A4 (enExample) |
| JP (2) | JP2004525108A (enExample) |
| KR (4) | KR20080036661A (enExample) |
| CN (3) | CN1982330B (enExample) |
| AT (1) | ATE535539T1 (enExample) |
| AU (3) | AU2002246688A1 (enExample) |
| CA (1) | CA2432096A1 (enExample) |
| ES (2) | ES2377931T5 (enExample) |
| IL (3) | IL156394A0 (enExample) |
| NZ (2) | NZ554405A (enExample) |
| WO (1) | WO2002056829A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
| US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
| US20030236265A1 (en) * | 2002-05-23 | 2003-12-25 | Sayada Chalom B. | Methods of treating bacterial infections and diseases associated therewith |
| WO2003103699A1 (en) | 2002-06-06 | 2003-12-18 | Vicuron Pharmaceuticals Inc. | Use of ramoplanin to treat diseases associated with the use of antibiotics |
| AU2003297916A1 (en) * | 2002-12-12 | 2004-07-09 | Activbiotics, Inc. | Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| WO2004054513A2 (en) * | 2002-12-12 | 2004-07-01 | Activbiotics, Inc. | Methods and compositions for treating and preventing ear infections |
| US7267624B2 (en) * | 2004-07-30 | 2007-09-11 | Acushnet Company | Golf ball dimple pattern |
| WO2008011136A2 (en) * | 2006-07-20 | 2008-01-24 | Sicor Inc. | Process for the preparation of solid sterile active pharmaceutical ingredient |
| WO2009144739A1 (en) * | 2008-05-26 | 2009-12-03 | Biocon Limited | Amorphous daptomycin and a method of purification thereof |
| WO2010095953A1 (en) | 2009-02-19 | 2010-08-26 | Axellia Pharmaceuticals Aps | Process for purifying lipopeptides |
| CN101830970B (zh) * | 2009-03-12 | 2012-06-27 | 成都雅途生物技术有限公司 | 一种高纯度达托霉素(Daptomycin)的纯化制备方法 |
| CN101899094B (zh) * | 2009-06-01 | 2012-11-21 | 安徽丰原发酵技术工程研究有限公司 | 一种高纯达托霉素的制备方法 |
| JP2013511522A (ja) * | 2009-11-23 | 2013-04-04 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ダプトマイシン製剤 |
| TWI606838B (zh) * | 2009-11-23 | 2017-12-01 | 庫比斯特製藥有限責任公司 | 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法 |
| KR101151878B1 (ko) * | 2010-06-08 | 2012-05-31 | 미원상사주식회사 | 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물 |
| CN102276696B (zh) * | 2010-06-09 | 2014-11-05 | 上海来益生物药物研究开发中心有限责任公司 | 达托霉素的纯化方法 |
| CN103429228B (zh) | 2011-01-05 | 2016-10-26 | 赫士睿股份有限公司 | 万古霉素的喷雾干燥 |
| KR101034663B1 (ko) * | 2011-03-18 | 2011-05-17 | 김태욱 | 손목 피로를 저감시키는 마우스 |
| CN102206694B (zh) * | 2011-04-06 | 2013-10-16 | 山东新时代药业有限公司 | 一种含有癸酸的缓释组合物 |
| KR20140037877A (ko) * | 2011-05-26 | 2014-03-27 | 큐비스트 파마슈티컬즈 인코포레이티드 | Cb-183,315 조성물 및 관련 방법 |
| CN102241732B (zh) * | 2011-05-30 | 2015-01-21 | 浙江海正药业股份有限公司 | 一种脂肽化合物的纯化方法 |
| EA032840B8 (ru) | 2011-06-22 | 2020-06-18 | Вайоми Терапеутикс Лимитед | Пролекарства на основе конъюгатов противогрибковых агентов и их применение |
| CN102875652A (zh) * | 2011-07-13 | 2013-01-16 | 北大方正集团有限公司 | 一种分离纯化达托霉素的方法 |
| WO2013012101A1 (ko) * | 2011-07-15 | 2013-01-24 | 미원상사주식회사 | 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물 |
| CN102718839B (zh) * | 2012-07-05 | 2017-05-24 | 鲁南新时代生物技术有限公司 | 一种分离纯化达托霉素的方法 |
| WO2014031681A1 (en) * | 2012-08-20 | 2014-02-27 | The University Of Chicago | Inhibiting gram positive bacteria |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| CN104387444B (zh) * | 2014-11-13 | 2017-12-08 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs‑2高纯度样品的制备方法 |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| CN109476704B (zh) * | 2016-04-08 | 2022-08-16 | 港大科桥有限公司 | 抗菌环脂肽 |
| IT201600127655A1 (it) | 2016-12-16 | 2018-06-16 | Gnosis Spa | Processo per la purificazione di antibiotici lipopolipeptidici |
| US10072045B1 (en) | 2017-06-26 | 2018-09-11 | Ramapo Pharmaceuticals, Inc. | Antibacterial lipopeptides and methods for their preparation and use |
| IT201800006314A1 (it) * | 2018-06-14 | 2019-12-14 | Uso di resine a scambio cationico per la purificazione di antibiotici lipopolipeptidici | |
| WO2020086931A1 (en) * | 2018-10-25 | 2020-04-30 | Cidara Therapeutics, Inc. | Polymorph of echinocandin antifungal agent |
| JP2022514597A (ja) | 2018-12-21 | 2022-02-14 | アレコー リミテッド | 新規組成物 |
| CN112979756B (zh) * | 2019-12-13 | 2023-01-03 | 浙江昌海制药有限公司 | 达托霉素的提纯方法 |
| CN113480623B (zh) * | 2021-08-09 | 2022-12-27 | 广州天赐高新材料股份有限公司 | 一种脂肽组合物及其制备方法和应用 |
| CN116726145A (zh) * | 2022-03-04 | 2023-09-12 | 海南普利制药股份有限公司 | 一种稳定的酯肽类药物组合物 |
| WO2024085235A1 (ja) * | 2022-10-20 | 2024-04-25 | 中外製薬株式会社 | 環状ペプチドの結晶の製造方法 |
| EP4631955A1 (en) * | 2022-12-28 | 2025-10-15 | Chugai Seiyaku Kabushiki Kaisha | Purification method and production method of cyclic peptide |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1021538B (de) † | 1954-06-04 | 1957-12-27 | Bristol Lab Inc | Verfahren zur Herstellung und Gewinnung einer antibiotisch wirkenden Verbindung |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| USRE31396E (en) * | 1978-10-16 | 1983-09-27 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| EP0014815A3 (de) * | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
| US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| ES520132A0 (es) | 1982-02-27 | 1984-04-01 | Beecham Group Plc | Un procedimiento para la preparacion de derivados de 1-normon-2-ilo. |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4537717A (en) * | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) * | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2533209B1 (fr) * | 1982-09-22 | 1985-11-08 | Centre Nat Rech Scient | Lipopeptides, leur obtention et leur application comme emulsifiants |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| CA1315229C (en) * | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
| EP0294990A3 (en) * | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| CA1337758C (en) * | 1988-04-11 | 1995-12-19 | Eli Lilly And Company | Peptide antibiotics |
| US5039789A (en) * | 1988-04-11 | 1991-08-13 | Eli Lilly And Company | A54145 cyclic peptides |
| US4994270A (en) * | 1988-04-11 | 1991-02-19 | Eli Lilly And Company | A54145 antibiotics and process for their production |
| US4886243A (en) * | 1988-10-26 | 1989-12-12 | Trumbull Christopher J | Hydraulic jack ramp |
| CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| US5202309A (en) | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| JPH04224197A (ja) * | 1990-12-26 | 1992-08-13 | Fujitsu Ltd | 生体高分子結晶化方法および装置 |
| US5369093A (en) * | 1991-03-15 | 1994-11-29 | Merck & Co., Inc. | Lipopeptide derivatives |
| US5336756A (en) * | 1991-05-01 | 1994-08-09 | Merck & Co., Inc. | Process for crystalline cyclic lipopeptides |
| TW213468B (enExample) * | 1991-06-29 | 1993-09-21 | Hoechst Ag | |
| US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
| ATE239431T1 (de) * | 1992-10-21 | 2003-05-15 | Gynetech Lab Inc | Abgabesystem bestehend aus einem vaginaschwamm |
| AU7497594A (en) | 1993-08-13 | 1995-03-14 | Smithkline Beecham Plc | Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity |
| DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5716960A (en) * | 1995-01-13 | 1998-02-10 | U.S. Bioscience Inc. And Individuals | Crystalline trimetrexate salts and the process for making the same |
| JP3067972B2 (ja) * | 1995-03-03 | 2000-07-24 | 新日本理化株式会社 | ジアセタールの六方晶結晶、該六方晶結晶を含む核剤、該六方晶結晶を含むポリオレフィン系樹脂組成物及び成形物、並びに該組成物の成形方法 |
| ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
| DE19546573A1 (de) * | 1995-12-13 | 1997-06-19 | Uetikon Chemie Gmbh | Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung |
| US5972331A (en) * | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| JP4711471B2 (ja) * | 1996-07-05 | 2011-06-29 | 三菱商事フードテック株式会社 | 結晶マルチトール及びそれを含有する含蜜結晶の製造方法 |
| US5696084A (en) * | 1996-08-16 | 1997-12-09 | Abbott Laboratories | Amino-lipopetide antifungal agents |
| US5928666A (en) * | 1996-11-12 | 1999-07-27 | Cygnus Inc. | Crystalline form of estradiol and pharmaceutical formulations comprising same |
| JP3569422B2 (ja) * | 1996-12-26 | 2004-09-22 | シャープ株式会社 | 結晶型オキソチタニルフタロシアニン及びそれを用いた電子写真感光体並びに画像形成方法 |
| US6017562A (en) * | 1997-04-28 | 2000-01-25 | Arch Chemicals, Inc. | Non-spherical and non-platelet crystalline forms of pyrithione salts |
| US5965747A (en) * | 1997-07-10 | 1999-10-12 | Merck & Co., Inc. | Crystalline forms of antibiotic side chain intermediates |
| WO1999042191A1 (en) * | 1998-02-18 | 1999-08-26 | Biospace International Inc. | Dynamically controlled crystallization method and apparatus and crystals obtained thereby |
| DE19807972A1 (de) † | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
| JP2003510245A (ja) | 1998-08-07 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | 抗生物質の製造方法 |
| EP1674107B8 (en) * | 1998-09-25 | 2017-01-25 | Cubist Pharmaceuticals LLC | Use of daptomycin |
| US6911525B2 (en) | 1999-12-15 | 2005-06-28 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
| CA2394350A1 (en) | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
| EP1240182A2 (en) | 1999-12-15 | 2002-09-18 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs and their use as antibacterial agents |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| WO2002059145A1 (en) † | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| US9394340B2 (en) † | 2009-03-24 | 2016-07-19 | Cadila Healthcare Limited | Purification process for lipopeptides |
-
2001
- 2001-12-17 WO PCT/US2001/048887 patent/WO2002056829A2/en not_active Ceased
- 2001-12-17 EP EP01994272A patent/EP1343811A4/en not_active Withdrawn
- 2001-12-17 IL IL15639401A patent/IL156394A0/xx unknown
- 2001-12-17 JP JP2002559447A patent/JP2004525108A/ja active Pending
- 2001-12-17 CN CN2006101485645A patent/CN1982330B/zh not_active Expired - Lifetime
- 2001-12-17 KR KR1020087007405A patent/KR20080036661A/ko not_active Withdrawn
- 2001-12-17 EP EP07124028.7A patent/EP1908770B2/en not_active Expired - Lifetime
- 2001-12-17 CN CNA018219373A patent/CN1592753A/zh active Pending
- 2001-12-17 EP EP10181862.3A patent/EP2261237B1/en not_active Expired - Lifetime
- 2001-12-17 KR KR1020097020735A patent/KR20090122469A/ko not_active Ceased
- 2001-12-17 AU AU2002246688A patent/AU2002246688A1/en not_active Abandoned
- 2001-12-17 US US10/023,517 patent/US20030045678A1/en not_active Abandoned
- 2001-12-17 KR KR10-2003-7008117A patent/KR20030081353A/ko not_active Ceased
- 2001-12-17 KR KR1020117023192A patent/KR20110127732A/ko not_active Ceased
- 2001-12-17 CN CN201010578392.1A patent/CN102070703B/zh not_active Expired - Lifetime
- 2001-12-17 US US10/024,701 patent/US20030045484A1/en not_active Abandoned
- 2001-12-17 CA CA002432096A patent/CA2432096A1/en active Pending
- 2001-12-17 NZ NZ554405A patent/NZ554405A/en not_active IP Right Cessation
- 2001-12-17 AT AT07124028T patent/ATE535539T1/de active
- 2001-12-17 ES ES07124028.7T patent/ES2377931T5/es not_active Expired - Lifetime
- 2001-12-17 ES ES10181862.3T patent/ES2691680T3/es not_active Expired - Lifetime
- 2001-12-17 AU AU2002246687A patent/AU2002246687C1/en not_active Ceased
- 2001-12-17 NZ NZ571597A patent/NZ571597A/en not_active IP Right Cessation
-
2003
- 2003-06-11 IL IL156394A patent/IL156394A/en not_active IP Right Cessation
-
2008
- 2008-03-03 JP JP2008051874A patent/JP4927003B2/ja not_active Expired - Lifetime
- 2008-08-25 AU AU2008207496A patent/AU2008207496B2/en not_active Ceased
-
2013
- 2013-12-30 IL IL230244A patent/IL230244A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525108A5 (enExample) | ||
| TWI659028B (zh) | 苯并咪唑衍生物（（Ｓ）-４-（５，７-二氟唍-４-基氧基）-Ｎ，Ｎ，２-三甲基-１Ｈ-苯并[ｄ]咪唑-６-甲醯胺）之酸加成鹽 | |
| JP5190350B2 (ja) | クラリスロマイシンの結晶形態０ | |
| ES2271375T3 (es) | Sales farmaceuticamente aceptables de alendronato en forma amorfa. | |
| CN108774200A (zh) | 化合物的结晶复合物，其制备方法及其用于制备药物的用途 | |
| KR101626506B1 (ko) | 에리트로마이신염의 수화물, 그의 제조방법 및 용도 | |
| SE449614B (sv) | (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamido/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylatpentahydrat, forfarande for dess framstellning och farmaceutisk komposition derav | |
| JPH0670057B2 (ja) | グアニン誘導体結晶性一水和物、その製造方法及びそれを含む抗ウイルス剤 | |
| JP2010132669A (ja) | ストロンチウムラネレートのアルファー（α）−結晶形、その製造方法、及びそれを含む医薬組成物 | |
| JP6678711B2 (ja) | マルトール第二鉄の結晶形態 | |
| SE505258C2 (sv) | Nya dihydrokloridhydrat av 7-(]0a]-(2aminotiazol-4-yl)-]0a]- (Z)-metoxiiminoacetamido)-3-((1-metylpyrrolidino)-metyl)-3- cefem-4-karboxylsyra i kristallin form | |
| WO2004104010A1 (en) | Crystalline form of cefdinir | |
| EP0882052A1 (en) | New cephem compounds and pharmaceutical use thereof | |
| CA1248088A (en) | Crystalline cephalosporin hydrohalid salts | |
| AU712904B2 (en) | Improved process for preparing potassium clavulanate | |
| JPH08511008A (ja) | 複素環式化学 | |
| TWI285204B (en) | Polymorphs of a crystalline azabicyclo[2,2.2]octan-3-amine citrate and their pharmaceutical compositions | |
| CA2460970A1 (en) | Processes for preparing crystalline and amorphous mupirocin calcium | |
| SE452323B (sv) | Kristallint 1,1-dioxopenicillanoyloximetyl-6-(d-alfa-amino-alfa-fenylacetamido) penicillanat-2-naftensulfonat och farmaceutiska kompositioner derav | |
| CN111233894B (zh) | 一种头孢妥仑匹酯δ3异构体的制备方法 | |
| JPS6011040B2 (ja) | 抗菌剤類の製法 | |
| JPH021489A (ja) | 結晶性β―ラクタム溶媒和物 | |
| JP2006511614A (ja) | ナテグリニドの多形性形状 | |
| HU210876A9 (en) | Arginine derivatives | |
| WO2006090263A1 (en) | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions |